Overview Dividends

(TEVA) Teva Pharma Industries - Ratings and Ratios

Exchange: NYSE • Country: Israel • Currency: USD • Type: Common Stock • ISIN: US8816242098

Generic Drugs, CNS Therapies, Respiratory Inhalers, Oncology Injections, OTC Creams

TEVA EPS (Earnings per Share)

EPS Growth (3Y CAGR): -29.20%
EPS Trend (3Y Correlation): -32.5%

TEVA Revenue

Revenue Growth (3Y CAGR): 5.60%
Revenue Trend (3Y Correlation): 62.1%

Description: TEVA Teva Pharma Industries October 14, 2025

Teva Pharmaceutical Industries Ltd. (NYSE: TEVA) is a global generic-drug leader that also markets a range of branded specialty medicines. Its product slate spans tablets, capsules, injectables, inhalers, transdermal patches, and combination devices, with a strategic focus on central nervous system, respiratory, and oncology therapies. In addition to manufacturing active pharmaceutical ingredients (APIs) and offering contract-manufacturing services, Teva runs an out-licensing platform that monetizes its extensive product portfolio.

Key branded assets include COPAXONE for multiple sclerosis, AJOVY (migraine prevention), UZEDY (schizophrenia), and oncology injectables BENDEKA and TREANDA. The company also sells OTC products under brands such as SUDOCREM and FLEGAMINA, and maintains collaborations with partners like Sanofi, Alvotech, and MedinCell to augment its pipeline and distribution reach.

As of FY 2023, Teva reported revenue of roughly $13.5 billion, with a net debt-to-EBITDA ratio of ≈ 3.2, reflecting ongoing balance-sheet deleveraging. The generic market is pressured by US pricing reforms and biosimilar competition, but growth in specialty injectables and the CNS segment offers a higher-margin offset. Assuming the company can sustain its 2024-2025 pipeline launches and maintain cost-discipline, the upside potential hinges on market share gains in the respiratory inhaler space and successful commercialization of its oncology injectables. For a deeper quantitative assessment, you may find the analytics on ValueRay useful for benchmarking TEVA’s valuation against sector peers.

TEVA Stock Overview

Market Cap in USD	21,750m
Sub-Industry	Pharmaceuticals
IPO / Inception	1990-03-26

TEVA Stock Ratings

Growth Rating	49.6%
Fundamental	48.9%
Dividend Rating	18.1%
Return 12m vs S&P 500	-12.6%
Analyst Rating	4.45 of 5

TEVA Dividends

Currently no dividends paid

TEVA Growth Ratios

Growth Correlation 3m	82.8%
Growth Correlation 12m	6%
Growth Correlation 5y	62.2%
CAGR 5y	28.90%
CAGR/Max DD 3y (Calmar Ratio)	0.66
CAGR/Mean DD 3y (Pain Ratio)	2.01
Sharpe Ratio 12m	-0.09
Alpha	-10.54
Beta	0.709
Volatility	38.25%
Current Volume	5210.8k
Average Volume 20d	8250.8k
Stop Loss	18.3 (-3.4%)
Signal	-0.31

Piotroski VR‑10 (Strict, 0-10) 2.0

Net Income (-158.0m TTM) > 0 and > 6% of Revenue (6% = 997.7m TTM)

FCFTA 0.02 (>2.0%) and ΔFCFTA -0.67pp (YES ≥ +1.0pp, WARN ≥ +0.5pp)

NWC/Revenue 4.56% (prev -8.62%; Δ 13.18pp) (YES ≤20% & Δ≤-1pp; WARN ≤25% & Δ≤0 oder ≤40% & Δ≤-3pp)

CFO/TA 0.03 (>3.0%) and CFO 1.39b > Net Income -158.0m (YES >=105%, WARN >=100%)

Net Debt (15.36b) to EBITDA (1.90b) ratio: 8.09 <= 3.0 (WARN <= 3.5)

Current Ratio 1.06 (target 1.5–3.0; WARN 1.2–<1.5 or >3.0–5.0; CFO/TA gate active)

Outstanding Shares last Quarter (1.16b) change vs 12m ago 2.47% (target <= -2.0% for YES)

Gross Margin 49.60% (prev 49.52%; Δ 0.07pp) >=18% & Δ>=+0.5pp (WARN >=15% & Δ>=0)

Asset Turnover 40.82% (prev 39.43%; Δ 1.39pp) >=50% & Δ>=+2pp (WARN >=35% & Δ>=0)

Interest Coverage Ratio 0.56 (EBITDA TTM 1.90b / Interest Expense TTM 1.55b) >= 6 (WARN >= 3)

Altman Z'' -1.46

(A) 0.02 = (Total Current Assets 12.62b - Total Current Liabilities 11.86b) / Total Assets 40.13b

(B) -0.37 = Retained Earnings (Balance) -14.68b / Total Assets 40.13b

(D) -0.51 = Book Value of Equity -17.05b / Total Liabilities 33.30b

Total Rating: -1.46 = (6.56 * A) + (3.26 * B) + (6.72 * C) + (1.05 * D)

ValueRay F-Score (Strict, 0-100) 48.90

1. Piotroski 2.0pt = -3.0

2. FCF Yield 2.66% = 1.33

3. FCF Margin 5.93% = 1.48

4. Debt/Equity 2.56 = -0.10

5. Debt/Ebitda 8.09 = -2.50

6. ROIC - WACC (= -0.74)% = -0.92

7. RoE -2.58% = -0.43

8. Rev. Trend 62.14% = 4.66

9. EPS Trend -32.53% = -1.63

What is the price of TEVA shares?

As of October 27, 2025, the stock is trading at USD 18.95 with a total of 5,210,800 shares traded.
Over the past week, the price has changed by -2.42%, over one month by +3.33%, over three months by +14.78% and over the past year by +3.16%.

Is Teva Pharma Industries a good stock to buy?

No, based on ValueRay´s Fundamental Analyses, Teva Pharma Industries (NYSE:TEVA) is currently (October 2025) a stock to sell. It has a ValueRay Fundamental Rating of 48.90 and therefor a negative outlook according to the companies health.
Based on momentum, paid dividends and discounted-cash-flow analyses, the fair value of TEVA is around 19.92 USD . This means that TEVA is currently overvalued and has a potential downside of 5.12%.

Is TEVA a buy, sell or hold?

Teva Pharma Industries has received a consensus analysts rating of 4.45. Therefore, it is recommended to buy TEVA.

Strong Buy: 6
Buy: 4
Hold: 1
Sell: 0
Strong Sell: 0

What are the forecasts/targets for the TEVA price?

Issuer	Target	Up/Down from current
Wallstreet Target Price	24.4	29%
Analysts Target Price	24.4	29%
ValueRay Target Price	21.7	14.4%

TEVA Fundamental Data Overview October 27, 2025

Market Cap USD = 21.75b (21.75b USD * 1.0 USD.USD)
P/E Forward = 7.0621
P/S = 1.308
P/B = 3.369
P/EG = 1.2934
Beta = 0.709
Revenue TTM = 16.63b USD
EBIT TTM = 875.0m USD
EBITDA TTM = 1.90b USD
Long Term Debt = 16.76b USD (from longTermDebt, last quarter)
Short Term Debt = 464.0m USD (from shortTermDebt, last quarter)
Debt = 17.52b USD (from shortLongTermDebtTotal, last quarter)
Net Debt = 15.36b USD (from netDebt column, last quarter)
Enterprise Value = 37.11b USD (21.75b + Debt 17.52b - CCE 2.16b)
Interest Coverage Ratio = 0.56 (Ebit TTM 875.0m / Interest Expense TTM 1.55b)
FCF Yield = 2.66% (FCF TTM 986.0m / Enterprise Value 37.11b)
FCF Margin = 5.93% (FCF TTM 986.0m / Revenue TTM 16.63b)
Net Margin = -0.95% (Net Income TTM -158.0m / Revenue TTM 16.63b)
Gross Margin = 49.60% ((Revenue TTM 16.63b - Cost of Revenue TTM 8.38b) / Revenue TTM)
Gross Margin QoQ = 50.34% (prev 48.24%)
Tobins Q-Ratio = 0.92 (Enterprise Value 37.11b / Total Assets 40.13b)
Interest Expense / Debt = 1.65% (Interest Expense 288.9m / Debt 17.52b)
Taxrate = -37.46% (negative due to tax credits) (-78.0m / 208.2m)
NOPAT = 1.20b (EBIT 875.0m * (1 - -37.46%)) [negative tax rate / tax credits]
Current Ratio = 1.06 (Total Current Assets 12.62b / Total Current Liabilities 11.86b)
Debt / Equity = 2.56 (Debt 17.52b / totalStockholderEquity, last quarter 6.83b)
Debt / EBITDA = 8.09 (Net Debt 15.36b / EBITDA 1.90b)
Debt / FCF = 15.58 (Net Debt 15.36b / FCF TTM 986.0m)
Total Stockholder Equity = 6.13b (last 4 quarters mean from totalStockholderEquity)
RoA = -0.39% (Net Income -158.0m / Total Assets 40.13b)
RoE = -2.58% (Net Income TTM -158.0m / Total Stockholder Equity 6.13b)
RoCE = 3.82% (EBIT 875.0m / Capital Employed (Equity 6.13b + L.T.Debt 16.76b))
RoIC = 5.06% (NOPAT 1.20b / Invested Capital 23.79b)
WACC = 5.79% (E(21.75b)/V(39.27b) * Re(8.63%) + D(17.52b)/V(39.27b) * Rd(1.65%) * (1-Tc(-0.37)))
Discount Rate = 8.63% (= CAPM, Blume Beta Adj.)
Shares Correlation 3-Years: 33.33 | Cagr: 1.05%
[DCF Debug] Terminal Value 79.56% ; FCFE base≈1.11b ; Y1≈1.37b ; Y5≈2.33b
Fair Price DCF = 30.90 (DCF Value 35.45b / Shares Outstanding 1.15b; 5y FCF grow 25.0% → 3.0% )
EPS Correlation: -32.53 | EPS CAGR: -29.20% | SUE: -1.69 | # QB: 0
Revenue Correlation: 62.14 | Revenue CAGR: 5.60% | SUE: -0.59 | # QB: 0

Additional Sources for TEVA Stock

News: Wall Street Journal | Benzinga | Yahoo Finance
Tweets: X | Stocktwits
Fund Manager Positions: Dataroma | Stockcircle